Mechanisms of quinolone action and microbial response

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue SUPPL. 1, 2003, Pages 29-35

  Hawkey, Peter M ^a,b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antibiotic action; Antibiotic resistance; Fluoroquinolones

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CHLORAMPHENICOL; CLINAFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; STREPTOMYCIN; SULFAFURAZOLE; TOBRAMYCIN; TRIMETHOPRIM; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL GENOME; BACTERIAL MUTATION; BACTERIUM ISOLATION; CELL CLONE; CHROMOSOME MAP; CHROMOSOME MUTATION; DRUG BINDING; DRUG MECHANISM; DRUG USE; ESCHERICHIA COLI; GENE LOCUS; GENE TRANSFER; GRAM NEGATIVE BACTERIUM; NONHUMAN; OUTER MEMBRANE; PLASMID; REVIEW;

ANTI-INFECTIVE AGENTS; BACTERIA; DNA GYRASE; DNA TOPOISOMERASE IV; DNA-BINDING PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; MUTATION; PORINS; QUINOLONES;

EID: 0038778553     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg207     Document Type: Review

References (43)

1. Drlica, K. & Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61, 377-92.
2. Tillotson, G. S., Dorrian, I. & Blondeau, J. (1997). Fluoroquinolone resistance: mechanisms and epidemiology. Journal of Medical Microbiology 46, 457-61.
3. Wiedemann, B. & Heisig, P. (1994). Mechanisms of quinolone resistance. Infection 22, Suppl. 2, S73-9.
4. Kato, J., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S. & Suzuki, H. (1990). New topoisomerase essential for chromosome segregation in E. coli. Cell 63, 393-404.
5. Khodursky, A. B. & Cozzarelli, N. R. (11998). The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. Journal of Biological Chemistry 273, 27668-77.
6. Zhao, X., Xu, C., Domagala, J. & Drlica, K. (1997). DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proceedings of the National Academy of Sciences, USA 94, 13991-6.
7. Chen, C. R., Malik, M., Snyder, M. & Drlica, K. (1996). DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. Journal of Molecular Biology 258, 627-37.
8. Hoshino, K., Kitamura, A., Morrissey, I., Sato, K., Kato, J. & Ikeda, H. (1994). Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy 38, 2623-7.
9. Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proceedings of the National Academy of Sciences, USA 92, 11801-5.
10. Pan, X. S. & Fisher, L. M. (1997). Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrobial Agents and Chemotherapy 41, 471-4.
11. Pan, X. S., Yague, G. & Fisher, L. M. (2001). Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrobial Agents and Chemotherapy 45, 3140-7.
12. Oizumi, N., Kawabata, S., Hirao, M., Watanabe, K., Okuno, S., Fujiwara, T. et al. (2001). Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. Journal of Infection and Chemotherapy 7, 191-4.
13. Zhao, X., Wang, J. Y., Xu, C., Dong, Y., Zhou, J., Domagala, J. et al. (1998). Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrobial Agents and Chemotherapy 42, 956-8.
14. Lu, T., Zhao, X., Li, X., Drlica-Wagner, A., Wang, J. Y., Domagala, J. et al. (2001). Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 45, 2703-9.
15. Dong, Y., Xu, C., Zhao, X., Domagala, J. & Drlica, K. (1998). Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrobial Agents and Chemotherapy 42, 2978-84.
16. Zhao, B. Y., Pine, R., Domagala, J. & Drlica K. (1999). Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrobial Agents and Chemotherapy 43, 661-6.
17. M'Zali, F. H., Hawkey, P. M. & Dalhoff, A. (1999). Differential selection of quinolone resistance by new quinolones in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. In Moxifloxacin in Practice (Adam, D. & Finch, R. G., Eds), pp. 61-9. Maxim Medical, Oxford, UK.
18. Dalhoff, A. (2001). Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clinical Infectious Diseases 32, Suppl. 1, S16-22.
19. Zhao, X. & Drlica, K. (2001). Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clinical Infectious Diseases 33, Suppl. 3, S147-56.
20. McGee, L., Goldsmith, C. E. & Klugman, K. P. (2002) Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. Journal of Antimicrobial Chemotherapy 49, 173-6.
21. Ho, P. L., Yam, W. C., Cheung, T. K., Ng, W. W., Que, T. L., Tsang, D. N. et al. (2001). Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerging Infectious Diseases 7, 906-8.
22. Nikaido, H. (1998). Antibiotic resistance caused by Gram-negative multidrug efflux pumps. Clinical Infectious Diseases 27, Suppl. 1, S32-41.
23. Li, X. Z., Livermore, D. M. & Nikaido, H. (1994). Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrobial Agents and Chemotherapy 38, 1732-41.
24. Poole, K., Krebes, K., McNally, C. & Neshat, S. (1993). Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. Journal of Bacteriology 175, 7363-72.
25. Ma, D., Cook, D. N., Alberti, M., Pon, N. G., Nikaido, H. & Hearst, J. E. (1993). Molecular cloning and characterization of acrA and acrE genes of Escherichia coli. Journal of Bacteriology 175, 6299-313.
26. Murakami, S., Nakashima, R., Yamashita, E. & Yamaguchi, A. (2002). Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419, 587-93.
27. Kaatz, G. W. & Seo, S. M. (1995) Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 2650-5.
28. Yu, J. L., Grinius, L. & Hooper, D. C. (2002). NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. Journal of Bacteriology 184, 1370-7.
29. Sun, L., Sreedharan, S., Plummer, K. & Fisher, L. M. (1996). NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations. Antimicrobial Agents and Chemotherapy 40, 1665-9.
30. Yamada, H., Kurose-Hamada, S., Fukuda, Y., Mitsuyama, J., Takahata, M., Minami, S. et al. (1997). Quinolone susceptibility of norA-disrupted Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 41, 2308-9.
31. Gill, M. J., Brenwald, N. P. & Wise, R. (1999). Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 43, 187-9.
32. Piddock, L. J., Johnson, M. M., Simjee, S. & Pumbwe, L. (2002). Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 46, 808-12.
33. Miyamae, S., Ueda, O., Yoshimura, F., Hwang, J., Tanaka, Y. & Nikaido, H. (2001). A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrobial Agents and Chemotherapy 45, 3341-6.
34. Onodera, Y. & Sato, K. (1999). Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrobial Agents and Chemotherapy 43, 2423-9.
35. Niga, T., Yoshida, H., Hattori, H., Nakamura, S. & Ito, H. (1997). Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 41, 1770-4.
36. Martinez-Martinez, L., Pascual, A. & Jacoby, G. A. (1998). Quinolone resistance from a transferable plasmid. Lancet 351, 797-9.
37. Jacoby, G. A., Chow, N. & Waites, K. (2001). Prevalence of plasmid-mediated quinolone resistance. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract 2120, p.145. American Society for Microbiology, Washington, DC, USA.
38. Ruiz, J., Casellas, S., Jimenez de Anta, M. T. & Vila, J. (1997). The region of the parE gene, homologous to the quinolone-resistance determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates. Journal of Antimicrobial Chemotherapy 39, 839-40.
39. Jorgensen, J. H., Weigel, L. M., Ferraro, M. J., Swenson, J. M. & Tenover, F. C. (1999). Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrobial Agents and Chemotherapy 43, 329-34.
40. Spoering, A. L. & Lewis, K. (2001). Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. Journal of Bacteriology 183, 6746-51.
41. Venezia, R. A., Domaracki, B. E., Evans, A. M., Preston, K. E. & Graffunder, E. M. (2001) Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. Journal of Antimicrobial Chemotherapy 48, 375-81.
42. Critchley, I. A., Blosser-Middleton, R. S., Jones, M. E., Karlowsky, J. A., Karginova, E. A., Thornsberry, C. et al. (2002). Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000. International Journal of Antimicrobial Agents 20, 100-7.
43. Brueggemann, A. B., Coffman, S. L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A. et al. (2002) Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrobial Aqents and Chemotherapy 46, 680-8.